Adagene Inc (ADAG) - Total Liabilities
Based on the latest financial reports, Adagene Inc (ADAG) has total liabilities worth $42.91 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ADAG asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Adagene Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Adagene Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Adagene Inc total assets.
Adagene Inc Competitors by Total Liabilities
The table below lists competitors of Adagene Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SCI Pharmtech Inc
TW:4119
|
Taiwan | NT$1.62 Billion |
|
Electromed Inc
NYSE MKT:ELMD
|
USA | $9.47 Million |
|
GE Power India Limited
NSE:GEPIL
|
India | Rs16.96 Billion |
|
Celon Pharma SA
WAR:CLN
|
Poland | zł141.95 Million |
|
W-SCOPE CHUNGJU PLANT LTD (PROPOSE
KQ:393890
|
Korea | ₩1.09 Trillion |
|
Arman Financial Services Limited
NSE:ARMANFIN
|
India | Rs18.64 Billion |
|
Teamlease Services Limited
NSE:TEAMLEASE
|
India | Rs-10.60 Billion |
|
SilverBox Corp IV
NYSE:SBXD
|
USA | $12.97 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Adagene Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ADAG net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Adagene Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Adagene Inc (2018–2025)
The table below shows the annual total liabilities of Adagene Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $42.91 Million | +10.76% |
| 2024-12-31 | $38.74 Million | -14.22% |
| 2023-12-31 | $45.17 Million | -34.83% |
| 2022-12-31 | $69.31 Million | +110.33% |
| 2021-12-31 | $32.95 Million | -81.02% |
| 2020-12-31 | $173.65 Million | +6.60% |
| 2019-12-31 | $162.90 Million | +70.68% |
| 2018-12-31 | $95.44 Million | -- |
About Adagene Inc
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 anti… Read more